Description
IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic, also known as HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC, PICD) is a member of isocitrate dehydrogenases, which catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. IDH1 is the NADP(+)-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. It contains the PTS-1 peroxisomal targeting signal sequence. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2, 4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production. Mutations in human cytosolic isocitrate dehydrogenase I (IDH1) occur somatically in >70% of grade II-III gliomas and secondary glioblastomas, and in 8.5% of acute myeloid leukemias (AML). Mutations have also been reported in cancers of the colon and prostate. To date, mutations in at least four active site arginine residues IDH1 R100, IDH1 R132, IDH2 R140, and IDH2 R172 have been shown to result in the neomorphic production of R(-)-2-hydroxyglutarate (2HG), although these mutants lack the wild-type enzyme's ability to convert isocitrate to a-ketoglutarate (a-KG, 2OG). Among of them, IDH1 R100A is affected in adult glioma.
Form
Recombinant IDH1 (R100A) protein is supplied at a concentration of 1.2 μg/μL in 25 mM Tris pH 8.0, 300 mM NaCl, 5% glycerol.